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The history of HIV is also the history of antiretroviral
therapy (ART), the single most important measure in
combating the HIV pandemic. The outcomes and in
particular the interpretation of some early ART trials
have greatly influenced the development of treatment
guidelines and the course of ART implementation. A
review of the development of NRTIs to date could be
seen as a handbook of cautionary tales, relevant to the
development of all future HIV therapies.
The early studies examining the use of acyclovir in the
treatment of HIV and the incremental implementation
of new drugs, progressing from mono and dual therapy
to triple ART therapy, are good examples of the influ-
ence that particular studies have had on the subsequent
treatment of HIV in the clinic. But the consistent mod-
est effects in trials were not always given sufficient con-
sideration and we did not always define the mechanisms
at work. A number of trials were also needed before we
understood that studying the right population - and
using the right combination of therapy - was essential, if
we were to avoid overlooking effective treatments
options. Other slowly-learned lessons were that long-
term follow-up studies are necessary to avoid those
complications that are not detected in standard trials;
they are also needed to detect in a reliable and timely
way those issues which raise safety concerns.
The progression to cART of course was not without
complications; good examples being the recognition and
investigation of the underlying mechanisms of lipody-
strophy, and the identification of an association between
abacavir and myocardial infarction. The development of
ART demonstrates the importance not only of the origi-
nal ART trials but also continued investigation of speci-
fic drugs and regimens in the clinic to identify and
manage any subsequent treatment issues that may
become apparent after the rollout of these therapies.
N R T I sa r et h eb a c k b o n eo ft h e r a p yb u to n l yt w od r u g s
in the class are presently preferred in the current guide-
lines and there are too few active candidates in the pipe-
line. The future of this essential component of cART is
uncertain.
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